The York Research Database

ETS transcription factor ELF3 (ESE-1) is a cell cycle regulator in benign and malignant prostate

Archer, L. K., Frame, F. M., Walker, H. F., Droop, A. P., McDonald, G. L. K., Kucko, S., Berney, D. M., Mann, V. M., Simms, M. S. & Maitland, N. J., 3 Apr 2022, (Accepted/In press)

Article in FEBS open bio

Expansion of the 4-(Diethylamino)benzaldehyde Scaffold to Explore the Impact on Aldehyde Dehydrogenase Activity and Antiproliferative Activity in Prostate Cancer

Ibrahim, A. I. M., Batlle, E., Sneha, S., Jiménez, R., Pequerul, R., Parés, X., Rüngeler, T., Jha, V., Tuccinardi, T., Sadiq, M., Frame, F., Maitland, N. J., Farrés, J. & Pors, K., 10 Mar 2022

Article in JOURNAL OF MEDICINAL CHEMISTRY

Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?

Maitland, N. J., 17 Jan 2021

Review article in Cancers

Aldehyde Dehydrogenases and Prostate Cancer: Shedding Light on Isoform Distribution to Reveal Druggable Target

Quattrini, L., Sadiq, M., Petrarolo, G., Maitland, N. J., Frame, F. M., Pors, K. & La Motta, C., 4 Dec 2020

Article in Biomedicines

Overexpression of Placental Growth Factor in Stromal Cells from Benign Prostatic Hyperplasia: Another Piece in the Puzzle?

Devlin, C., Frame, F. M., Archer, L., Mann, V. M., Walker, H., Simms, M. S., Berney, D. M., Collins, A. & Maitland, N. J., 14 Sep 2020, (E-pub ahead of print)

Article in European Urology Open Science

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth

Casara, P., Davidson, J., Claperon, A., Toumelin-Braizat, G. L., Vogler, M., Bruno, A., Chanrion, M., Lysiak-Auvity, G., Diguarher, T. L., Starck, J-B., Chen, I., Whitehead, N., Graham, C., Matassova, N., Dokurno, P., Pedder, C., Wang, Y., Qiu, S., Girard, A-M., Schneider, E. & 18 others, Gravé, F., Studeny, A., Guasconi, G., Rocchetti, F., Maïga, S., Henlin, J-M., Colland, F., Kraus-Berthier, L., Gouill, S. L., Dyer, M. JS., Hubbard, R., Wood, M., Amiot, M., Cohen, G. M., Hickman, J. A., Morris, E., Murray, J. & Geneste, O., 13 Apr 2018

Article in Oncotarget

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer

Butler, D. E., Marlein, C., Walker, H. F., Frame, F. M., Mann, V. M., Simms, M. S., Davies, B. R., Collins, A. T. & Maitland, N. J., 23 May 2017

Article in Oncotarget

IK channel activation increases tumor growth and induces differential behavioral responses in two breast epithelial cell lines

Thurber, A., Nelson, M., Frost, C., Levin, M., Brackenbury, W. J. & Kaplan, D. L., 21 Mar 2017

Article in Oncotarget

Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia

Laidlaw, K. M. E., Berhan, S., Liu, S., Silvestri, G., Holyoake, T. L., Frank, D. A., Aggarwal, B., Bonner, M. Y., Perrotti, D., Jørgensen, H. G. & Arbiser, J. L., 9 Aug 2016

Article in Oncotarget

Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers

Rane, J. K., Erb, H. H., Nappo, G., Mann, V. M., Simms, M. S., Collins, A. T., Visakorpi, T. & Maitland, N. J., 21 Jun 2016

Article in Oncotarget